Clinical trials: Subcutaneous Injection
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
This single arm study assessed the efficacy and safety of subcutaneous methoxy polyethylene glycol-epoetin beta (Mircera), a continuous erythropoietin receptor activator (C.E.R.A.), for correction and/or maintenance of hemoglobin…
- Trial name
- NCT00642668
- Testing
- methoxy polyethylene glycol-epoetin beta
- Where
- 32 sites in Belgium
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Moderate or Severe Submental Fullness
Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
To evaluate the safety and potential efficacy of deoxycholic acid injection compared to placebo for the reduction of submental fat (fat below the chin).
- Trial name
- ATX-101 (NCT00618722)
- Testing
- Deoxycholic Acid Injection
- Where
- 6 sites in Australia, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Kythera Biopharmaceuticals
Juvenile Idiopathic Arthritis
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in participants aged 2-17 years with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) in order to identify the dose and regimen for adequate…
- Trial name
- SKYPP (NCT02776735)
- Testing
- Sarilumab
- Where
- 30 sites in United States, Argentina and 13 more
- Volunteers
- 102 people
- Sponsor
- Sanofi
Opioid Use Disorder
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD).
- Trial name
- NCT05704543
- Testing
- Buprenorphine Extended-Release Injection
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- Indivior Inc.
Rheumatoid Arthritis
A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive
The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate, as compared to methotrexate alone in rheumatoid arthritis subjects who have not been previously treated…
- Trial name
- NCT00264537
- Testing
- Methotrexate capsules, Golimumab 50 mg injections, Golimumab 100 mg injections
- Where
- 75 sites in United States, Argentina and 19 more
- Volunteers
- 637 people
- Sponsor
- Centocor, Inc.
Relapsing Remitting Multiple Sclerosis
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the…
- Trial name
- NCT00337779
- Testing
- Glatiramer Acetate (GA) 40 mg, glatiramer acetate 20 mg
- Volunteers
- 1,155 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Type 1 Diabetes Mellitus
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
The primary objectives of this study are to compare the difference in glycosylated hemoglobin (HbA1c) from baseline to Month 6 using Hylenex recombinant preadministration in continuous subcutaneous insulin infusion (CSII) versus…
- Trial name
- NCT01848990
- Testing
- Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro
- Where
- 39 sites in United States
- Volunteers
- 456 people
- Sponsor
- Halozyme Therapeutics
Stable Coronary Artery Disease
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly.
- Trial name
- NCT03384966
- Testing
- Selatogrel
- Where
- 20 sites in United States, Canada and 6 more
- Volunteers
- 346 people
- Sponsor
- Viatris Innovation GmbH
Neuropathic Back Pain, Spinal Cord Injury
Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury
Back pain is a common secondary condition of both acute and chronic spinal cord injury (SCI). Current existing treatment including both pharmacologic and non-pharmacologic are limited by marginal efficacy or intolerable side…
- Trial name
- NCT02736890
- Testing
- Botulinum Toxin A
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pain
OLP-1002 is Being Studied in the Treatment of Pain.
The primary objective of the study is to assess the safety and tolerability of single and multiple subcutaneous doses of OLP-1002 in healthy subjects.
- Trial name
- NCT03760913
- Testing
- OLP-1002 (Test): Part A, Single Ascending Dose, OLP-1002 (Test): Part B, Multiple Ascending Dose
- Where
- United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- OliPass Corporation
Relapsing-Remitting Multiple Sclerosis
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- GLOW (NCT01578785)
- Testing
- Glatiramer Acetate
- Where
- 169 sites in United States, Albania and 17 more
- Volunteers
- 178 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Opioid-use Disorder
SUBLOCADE Rapid Initiation Study
This study is to evaluate the safety and tolerability of initiating SUBLOCADE™ treatment following a shorter period of transmucosal (TM) buprenorphine treatment.
- Trial name
- NCT03993392
- Testing
- TM buprenorphine, SUBLOCADE
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Indivior Inc.
Ulcerative Colitis
Special Investigation in Patients With Ulcerative Colitis
This investigation will be conducted to obtain the following information regarding the use of Humira 40 mg Syringe 0.8 mL for Subcutaneous Injection in patients with Ulcerative Colitis. 1.
- Trial name
- NCT01947816
- Volunteers
- 1,621 people
- Sponsor
- AbbVie
Opioid Use Disorders
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and…
- Trial name
- NCT02651584
- Testing
- CAM2038 SC injection, SL BPN/NX tabs
- Where
- 36 sites in United States
- Volunteers
- 428 people
- Sponsor
- Braeburn Pharmaceuticals